Amgen's Statin Intolerance Study May Not Cure What Ails PCSK9 Inhibitors
This article was originally published in Scrip
Executive Summary
Amgen Inc.'s well-designed GAUSS-3 study shows a role of its PCSK9 inhibitor Repatha in patients who truly can't tolerate statins, but how this translates into real-world utilization in the highly cost-conscious cardiology space remains to be seen.
You may also be interested in...
PCSK9 Inhibitor Labeling Parity Is Within Reach As Praluent And Repatha Strive To Make Commercial Case
Sanofi and Regeneron’s Praluent could draw even with Amgen’s US Repatha in approved FDA indications in 2019. While the injectable PCSK9 inhibitors battle for payers and prescribers, Esperion is readying its oral bempedoic acid to join the lipid-lowering fray – and strategizing towards what could be the first statin intolerance indication.
Can Cholesterol Drug Sponsors Make The Case For Statin Intolerance?
Amgen's FOURIER outcomes study of Repatha supports LDL-lowering in high risk patients, but price may have to come down dramatically to spur wide use of the PCSK9 inhibitors with the subjective condition of statin intolerance.
Generic Crestor Marks The End Of An Era, Should Quickly Outperform PCSK9s
The launch of generic rosuvastatin offers yet another way to calculate the disappointing performance of the PCSK9 inhibitors.